Chinese Medical E-ournals Database
Adv Search
中华妇幼临床医学杂志(电子版)

Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition) ›› 2021, Vol. 17 ›› Issue (06): 650 -656. doi: 10.3877/cma.j.issn.1673-5250.2021.06.005

Forum

Current situation of relationship between tissue factor pathway inhibitor and pregnancy-related diseases

Bing Li1,1, Tingting Xu2,2, Lili Zhu1,1, Ning Li2,2, Aiqun Xu3,3, Jun Zhang2,2, Shuhong Li2,2,†()   

  • Received:2021-03-04 Revised:2021-10-28 Published:2021-12-01
  • Corresponding author: Shuhong Li
  • Supported by:
    Key Laboratory Project of Fertility Control Technology of National Health and Family Planning Commission(2018KF005); National Natural Science Foundation of China for Youths(81701453); Yantai Science and Technology Plan Project(2020YD001)
HTML ( ) PDF ( )

Tissue factor pathway inhibitor (TFPI) is a high molecular weight protein in human plasma. TFPI is divided into TFPI-1 and TFPI-2 subtypes. TFPI is widely expressed in human cells and participates in the process of blood coagulation. Nowadays, studies have found that expression of TFPI plays an important role in the occurrence and development of heart disease, various pregnancy-related diseases, such as preeclampsia (PE), hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome, amniotic fluid embolism (AFE), hematopathy, sepsis, and tumor. The author intends to elaborate on basic characteristics of human TFPI-1 and TFPI-2 subtypes, distribution of human TFPI-1 subtype, mechanism of inhibiting blood coagulation, and its relationship with pregnancy-related diseases, and latest research status of distribution of human TFPI-2 subtype and its relationship with pregnancy-related diseases, in order to provide new ideas and strategies for diagnosis and gene therapy of TFPI in pregnancy-related diseases.

Key words: Thromboplastin, Tissue factor pathway inhibitor, human, Pregnancy complications, Molecular targeted therapy, Disseminated intravascular coagulation, Pre-eclampsia, Embolism, amniotic fluid
[1]
Chowdary P. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia[J]. Int J Hematol, 2020, 111(1): 42-50. DOI: 10.1007/s12185-018-2548-6.
[2]
Grover SP, Mackman N. Tissue factor in atherosclerosis and atherothrombosis[J]. Atherosclerosis, 2020, 307: 80-86. DOI: 10.1016/j.atherosclerosis.2020.06.003.
[3]
Wood JP, Ellery PE, Maroney SA, et al. Biology of tissue factor pathway inhibitor[J]. Blood, 2014, 123(19): 2934-2943. DOI: 10.1182/blood-2013-11-512764.
[4]
Augustsson C, Svensson A, Kjaer B, et al. Factor Ⅹa and Ⅶa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain[J]. J Thromb Haemost, 2018, 16(5): 893-904. DOI: 10.1111/jth.14000.
[5]
Mehic D, Tolios A, Hofer S, et al. Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency[J]. Blood Adv, 2021, 5(2): 391-398. DOI: 10.1182/bloodadvances.2020003464.
[6]
Korte W, Graf L. The potential close future of hemophilia treatment - gene therapy, TFPI inhibition, antithrombin silencing, and mimicking factor Ⅷ with an engineered antibody[J]. Transfus Med Hemother, 2018, 45(2): 92-96. DOI: 10.1159/000488152.
[7]
Winckers K, Thomassen S, Ten Cate H, et al. Platelet full length TFPI-α in healthy volunteers is not affected by sex or hormonal use[J]. PLoS One, 2017, 12(2): e0168273. DOI: 10.1371/journal.pone.0168273.
[8]
Maroney SA, Ferrel JP, Collins ML, et al. Tissue factor pathway inhibitor-gamma is an active alternatively spliced form of tissue factor pathway inhibitor present in mice but not in humans[J]. J Thromb Haemost, 2008, 6(8): 1344-1351. DOI: 10.1111/j.1538-7836.2008.03033.x.
[9]
Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein[J]. Arterioscler Thromb Vasc Biol, 2016, 36(1): 9-14. DOI: 10.1161/ATVBAHA.115.305996.
[10]
Wood JP, Petersen HH, Yu B, et al. TFPIα interacts with FⅤa and FⅩa to inhibit prothrombinase during the initiation of coagulation[J]. Blood Adv, 2017, 1(27): 2692-2702. DOI: 10.1182/bloodadvances.2017011098.
[11]
Peterson JA, Maroney SA, Mast AE. Targeting TFPI for hemophilia treatment[J]. Thromb Res, 2016, 141(Suppl 2): S28-S30. DOI: 10.1016/S0049-3848(16)30359-0.
[12]
Reglińska-Matveyev N, Andersson HM, Rezende SM, et al. TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain[J]. Blood, 2014, 123(25): 3979-3987. DOI: 10.1182/blood-2014-01-551812.
[13]
Leal de Azeredo E, Solórzano VE, de Oliveira DB, et al. Increased circulating procoagulant and anticoagulant factors as TF and TFPI according to severity or infecting serotypes in human dengue infection[J]. Microbes Infect, 2017, 19(1): 62-68. DOI: 10.1016/j.micinf.2016.08.005.
[14]
Peraramelli S, Thomassen S, Heinzmann A, et al. Role of exosite binding modulators in the inhibition of FⅩa by TFPI[J]. Thromb Haemost, 2016, 115(3): 580-590. DOI: 10.1160/TH15-04-0354.
[15]
Ahnström J, Andersson HM, Hockey V, et al. Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S[J]. Blood, 2012, 120(25): 5059-5062. DOI: 10.1182/blood-2012-05-432005.
[16]
Siebert AE, Maroney SA, Martinez ND, et al. Intrauterine lethality in TFPI gene disrupted mice is differentially suppressed during mid- and late-gestation by platelet TFPIα overexpression[J]. J Thromb Haemost, 2021, 19(6): 1483-1492. DOI: 10.1111/jth.15299.
[17]
Castillo MM, Yang Q, Zhan M, et al. Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency[J]. Blood Adv, 2019, 3(3): 489-498. DOI: 10.1182/bloodadvances.2018018853.
[18]
张华，张红英，袁宁霞，等. 正常足月产妇羊水组织因子水平与妊娠高凝状态、羊水栓塞的关系研究[J]. 检验医学与临床，2016, 16(3): 322-324. DOI: 10.3969/j.issn.1672-9455.2016.03.014.
[19]
Uszyński W, Zekanowska E, Uszyński M, et al. New observations on procoagulant properties of amniotic fluid: microparticles (MPs) and tissue factor-bearing MPs (MPs-TF), comparison with maternal blood plasma[J]. Thromb Res, 2013, 132(6): 757-760. DOI: 10.1016/j.thromres.2013.10.001.
[20]
Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis[J]. Lancet Glob Health, 2014, 2(6): e323-e333. DOI: 10.1016/S2214-109X(14)70227-X.
[21]
熊钰，楼懿婷，蔡旭，等. 子痫前期孕妇分娩前后出凝血功能动态改变[J]. 中国实用妇科与产科杂志，2013, 29(3): 200-203.
[22]
王晓丹，韩翠欣，班玲，等. 组织因子及其抑制物在妊娠期高血压疾病患者血浆中的表达及临床意义[J]. 中国计划生育和妇产科，2016, 8(8): 51-54. DOI: 10.3969/j.issn.1674-4020.2016.08.15.
[23]
Luo C, Pook E, Wang F, et al. ADTRP regulates TFPI expression via transcription factor POU1F1 involved in coronary artery disease[J]. Gene, 2020, 753: 144805. DOI: 10.1016/j.gene.2020.144805.
[24]
Chen D, Xia M, Hayford C, et al. Expression of human tissue factor pathway inhibitor on vascular smooth muscle cells inhibits secretion of macrophage migration inhibitory factor and attenuates atherosclerosis in ApoE-/- mice[J]. Circulation, 2015, 131(15): 1350-1360. DOI: 10.1161/CIRCULATIONAHA.114.013423.
[25]
Efthymiou M, Arachchillage DRJ, Lane PJ, et al. Antibodies against TFPI and protein C are associated with a severe thrombotic phenotype in patients with and without antiphospholipid syndrome[J]. Thrombosis Res, 2018, 170: 60-68. DOI: 10.1016/j.thromres.2018.08.003.
[26]
Fei X, Wang H, Yuan W, et al. Tissue factor pathway inhibitor-1 is a valuable marker for the prediction of deep venous thrombosis and tumor metastasis in patients with lung cancer[J]. Biomed Res Int, 2017, 2017: 8983763. DOI: 10.1155/2017/8983763.
[27]
Zhao XP, He SW, Yue B, et al. Molecular characterization, expression analysis, and bactericidal activity of the derivative peptides of TFPI-1 and TFPI-2 in half-smooth tongue sole, Cynoglossus semilaevis[J]. Fish Shellfish Immunol, 2016, 58: 563-571. DOI: 10.1016/j.fsi.2016.10.003.
[28]
He SW, Zhang J, Li NQ, et al. A TFPI-1 peptide that induces degradation of bacterial nucleic acids, and inhibits bacterial and viral infection in half-smooth tongue sole, Cynoglossus semilaevis[J]. Fish Shellfish Immunol, 2017, 60: 466-473. DOI: 10.1016/j.fsi.2016.11.029.
[29]
白英，史旭波，郭诗东. 组织因子途经抑制物基因对血管内皮细胞分泌层黏连蛋白的影响[J]. 临床荟萃，2013, 28(10): 1116-1119. DOI: 10.3969/j.issn.1004-583X.2013.10.013.
[30]
傅羽，王世鹏，胡晶，等. 腺病毒介导TFPI基因转染诱导血管平滑肌细胞凋亡机制的探讨[J]. 哈尔滨医科大学学报，2013, 47(1): 19-23. DOI: 10.3969/j.issn.1000-1905.2013.01.005.
[31]
马丹丹，李辉，傅羽，等. TFPI基因转染对血管平滑肌细胞中细胞凋亡抑制蛋白的调控[J]. 中国动脉硬化杂志，2015, 23(8): 769-773.
[32]
Fazil MHUT, Chalasani MLS, Choong YK, er al. A C-terminal peptide of TFPI-1 facilitates cytosolic delivery of nucleic acid cargo into mammalian cells[J]. Biochimica Biophys Acta Biomembr, 2020, 1862(2): 183093. DOI: 10.1016/j.bbamem.2019.183093.
[33]
Kamei S, Kazama Y, Kuijper JL, et al. Genomic structure and promoter activity of the human tissue factor pathway inhibitor-2 gene[J]. Biochim Biophys Acta, 2001, 1517(3): 430-435. DOI: 10.1016/s0167-4781(00)00298-0.
[34]
Wang G, Zeng Y, Chen S, et al. Localization of TFPI-2 in the nucleus modulates MMP-2 gene expression in breast cancer cells[J]. Sci Rep, 2017, 7(1): 13575. DOI: 10.1038/s41598-017-14148-8
[35]
Egan K, O′Connor H, Kevane B, et al. Elevated plasma TFPI activity causes attenuated TF-dependent thrombin generation in early onset preeclampsia[J]. Thromb Haemost, 2017, 117(8): 1549-1557. DOI: 10.1160/TH16-12-0949.
[36]
Macdonald TM, Tong S, Myers J, et al. Circulating tissue factor pathway inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia[J]. Placenta, 2021, 105: 32-40. DOI: 10.1016/j.placenta.2021.01.018.
[37]
Karaszi K, Szabo S, Juhasz K, et al. Increased placental expression of placental protein 5 (PP5)/tissue factor pathway inhibitor-2 (TFPI-2) in women with preeclampsia and HELLP syndrome: relevance to impaired trophoblast invasion？[J]. Placenta, 2019, 76: 30-39. DOI: 10.1016/j.placenta.2019.01.011.
[38]
Xiao X, Tao X, Wang YX, et al. Hypomethylation of tissue factor pathway inhibitor 2 in human placenta of preeclampsia[J]. Thromb Res, 2017, 152: 7-13. DOI: 10.1016/j.thromres.2017.02.005.
[39]
Zheng L, Huang J, Su Y, et al. Vitexin ameliorates preeclampsia phenotypes by inhibiting TFPI-2 and HIF-1α/VEGF in a l-NAME induced rat model[J]. Drug Dev Res, 2019, 80(8): 1120-1127. DOI: 10.1002/ddr.21596.
[40]
Zheng LL, Huang J, Su Y, et al. Overexpression of tissue factor pathway inhibitor 2 attenuates trophoblast proliferation and invasion in preeclampsia[J]. Hum Cell, 2020, 33(3): 512-520. DOI: 10.1007/s13577-020-00322-0.
[41]
Andresen MS, Stavik B, Sletten M, et al. Indirect regulation of TFPI-2 expression by miR-494 in breast cancer cells[J]. Sci Rep, 2020, 10(1): 4036. DOI: 10.1038/s41598-020-61018-x.
[42]
Cao Y, Guo C, Yin Y, et al. Lysine-specific demethylase 2 contributes to the proliferation of small cell lung cancer by regulating the expression of TFPI-2[J]. Mol Med Rep, 2018, 18(1): 733-740. DOI: 10.3892/mmr.2018.9047.
[43]
程春郁，任占军，黄丹华，等. TFPI-2对缺氧大鼠星形胶质细胞生物学特性及机制的研究[J]. 中国免疫学杂志，2019, 35(9): 1047-1052. DOI: 10.3969/j.issn.1000-484X.2019.09.005.
[44]
Dong YL, Tan QF, Tao L, et al. Hypermethylation of TFPI2 correlates with cervical cancer incidence in the Uygur and Han populations of Xinjiang, China[J]. Int J Clin Exp Pathol, 2015, 8(2): 1844-1854.
[45]
孟斐. 组织因子途径抑制物-2在宫颈癌中的表达及其对宫颈癌细胞增殖、凋亡的影响[J]. 中国老年学杂志，2015, 35(1): 52-55. DOI: 10.3969/j.issn.1005-9202.2015.01.026.
[46]
李娜，熊娇，史明媚，等. 宫颈癌组织中组织因子途径抑制物-2表达变化及其与VEGF表达、微血管密度的相关性[J]. 山东医药，2018, 58(3): 59-61. DOI: 10.3969/j.issn.1002-266X.2018.03.018.
[47]
He SW, Wang JJ, Du X, et al. A teleost TFPI-2 peptide that possesses a broad antibacterial spectrum and immune-stimulatory properties[J]. Fish Shellfish Immunol, 2018, 82: 469-475. DOI: 10.1016/j.fsi.2018.08.051.
[48]
Kasetty G, Smeds E, Holmberg E, et al. Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections[J]. BMC Microbiol, 2016, 16(1): 129. DOI: 10.1186/s12866-016-0750-3.
[49]
Zhang M, Yue B, Zhang AH, et al. TC38, a teleost TFPI-2 peptide that kills bacteria via penetration of the cell membrane and interaction with nucleic acids[J]. Fish Shellfish Immunol, 2017, 64: 104-110. DOI: 10.1016/j.fsi.2017.03.001.
[50]
Papareddy P, Kalle M, Sørensen OE, et al. The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis[J]. PLoS Pathog, 2013, 9(12): e1003803. DOI: 10.1371/journal.ppat.1003803.
[51]
Ali MN, Kasetty G, Elvén M, et al. TFPI-2 protects against gram-negative bacterial infection[J]. Front Immunol, 2018, 9: 2072. DOI: 10.3389/fimmu.2018.02072.
[1] Xin Lu, Xin Wei, Zhibin Wang. Clinical efficacy of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a meta-analysis[J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2023, 16(02): 123-129.
[2] Haoyuan Yang, Jie Gong, Qingwei Zou, Hang Ruan. Current research status on adverse pregnancy outcomes of maternal and infant in pregnant women with asthma[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 522-529.
[3] Lu Wang, Yang Fan. Advances in endometrial cancer-related biomarker research[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 511-516.
[4] Changsheng Lin, Jun Zhan, Xue Xiao. Genetic testing and precision molecular targeted therapy in diagnosis and treatment of epithelial ovarian caner[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 505-510.
[5] Minrong Ma, Cong Li, Qin Zhou. Current research status of treatment of cervical cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 497-504.
[6] Lili Lou, Hanmin Liu. Current research status of susceptibility genes and epigenetics on childhood asthma[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(03): 249-255.
[7] Yanyan Liu, Xi Tan, Xue Peng. Pregnancy complicated with papillary urothelial neoplasms of low malignant potential: a case report and literature review[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(02): 212-218.
[8] Xiaofang Zhang, Ping Wang. Research progress on diagnosis and therapy for vaginal melanoma[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(06): 621-626.
[9] Kankan Gao, Huamin Zhong, Yongqiang Xie, Qiulian Deng, Fei Gao, Jielin Wang, Yan Long. Female genitourinary tract Mycoplasma infection and its resistance rate[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2022, 18(05): 569-576.
[10] Yujie Xu, Guodong Zhao. Advances and challenges in the treatment of advanced gastric cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 451-455.
[11] Xiaoyong Wei. Discussion on the focus issues of conversion therapy for primary liver cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 602-607.
[12] Shiming Li, Wei Huang, Ling Liu. Mechanism of high mobility group box protein 1 mediated sepsis-induced coagulopathy and treatment progress[J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2023, 09(03): 269-273.
[13] Zhen Chen, Hongbo Qi. Thrombophilia and fetal growth restriction[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2023, 12(01): 18-21.
[14] Xiao Lang, Weiwei Cheng. Iron deficiency and anemia in pregnancy[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2022, 11(04): 202-207.
[15] Chunyuan Luo, Hangxin Liu, Yue Li, Yanmei Mai, Lingbo Shi. Postpartum acquired hemophilia A: a case report and review of the literature[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(02): 114-117,123.
Viewed
Full text


Abstract

Copyright © Chinese Medical Association, Chinese Medical Multimedia Press  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号